This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by ABSHAGEN, U. Articles by OELKERS, W. Search for Related Content PubMed PubMed Citation Articles by ABSHAGEN, U. Articles by OELKERS, W.

Increased Plasma 11-Deoxycorticosterone During Spironolactone Medication

Department of Internal Medicine and Department of Clinical Pharmacology, Freie Universität Berlin Berlin, W. Germany

^* Reprint requests to: U. Abshagen, Department of Internal Medicine, Klinikum Steglitz, Freie Universitat Berlin, Hindenburgdamm 30, D-1000 Berlin 45, W. Germany.

The increase of plasma deoxycorticosterone (DOC) levels after administration of spironolactone is a real effect and not due to crossinterference of the drug or its metabolites with the DOC-assay. This is proved by in vitro and in vivo results. Of all the metabolites only canrenone interferes to some extent with DOC after liquidliquid- extraction and paper chromatography. The antiserum, however, is so highly specific, that the final cross-interference of the total procedure amounts to less than 2% of the DOC plasma levels. Moreover, in patients with Addison's disease only a very small increase of DOC plasma levels can be observed after administration of spironolactone in contrast to normal subjects.

Supported in part by the Deutsche Forschungsgemeinschaft (Ab 28/1).

Received August 30, 1976.